Transgene Biotek Profile
Key Indicators
- Authorised Capital ₹ 76.00 Cr
as on 24-12-2024
- Paid Up Capital ₹ 75.77 Cr
as on 24-12-2024
- Company Age 34 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 11.03 Cr
as on 24-12-2024
- Satisfied Charges ₹ 3.92 Cr
as on 24-12-2024
- Revenue -22.98%
(FY 2023)
- Profit 42.24%
(FY 2023)
- Ebitda -127.08%
(FY 2023)
- Net Worth -3049.61%
(FY 2023)
- Total Assets -12.74%
(FY 2023)
About Transgene Biotek
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 526139.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 76.00 Cr and a paid-up capital of Rs 75.77 Cr.
The company currently has active open charges totaling ₹11.03 Cr. The company has closed loans amounting to ₹3.92 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Transgene Biotek Limited. India are Chowdari Prasad as CFO and Ankita Jain as Company Secretary. Kollipara Rao, Santhosh Kumar, Sujana Kadiam, and One other member serve as directors at the Company.
- CIN/LLPIN
L85195TG1990PLC011065
- Company No.
011065
- Stock Symbol
BSE : 526139
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
01 Mar 1990
- Date of AGM
30 Dec 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Listed
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Medak, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Transgene Biotek?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kollipara Rao  | Managing Director | 04-Mar-2020 | Current |
| Chowdari Prasad | CFO | 24-May-2019 | Current |
| Ankita Jain | Company Secretary | 24-May-2019 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Swetha Marri | Director | 03-Jun-2020 | Current |
| Santhosh Kumar | Director | 12-Nov-2019 | Current |
| Sujana Kadiam | Director | 17-Apr-2015 | Current |
Financial Performance of Transgene Biotek.
Transgene Biotek Limited., for the financial year ended 2023, experienced significant reduction in revenue, with a 22.98% decrease. The company also saw a substantial improvement in profitability, with a 42.24% increase in profit. The company's net worth observed a substantial decline by a decrease of 3049.61%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Transgene Biotek?
In 2023, Transgene Biotek had a promoter holding of 21.68% and a public holding of 78.32%. The company had 1 Subsidiary. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Department Of Biotechnology Creation Date: 08 Apr 2010 | ₹5.07 Cr | Open |
Ge Capital Services India Creation Date: 30 Jul 2008 | ₹0.86 M | Open |
The Karur Vysya Bank Ltd. Creation Date: 30 May 2005 | ₹5.94 M | Open |
How Many Employees Work at Transgene Biotek?
Unlock and access historical data on people associated with Transgene Biotek, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Transgene Biotek, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Transgene Biotek's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
